These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 36214583)

  • 1. Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Pan J; Liu Y; Guo X; Bai Z; Levi Sandri GB; Méndez-Sánchez N; Qi X
    Expert Opin Drug Saf; 2022 Oct; 21(10):1275-1287. PubMed ID: 36214583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers.
    Yamamoto A; Yano Y; Ueda Y; Yasutomi E; Hatazawa Y; Hayashi H; Yoshida R; Asaji N; Shiomi Y; Tobimatsu K; Sakai A; Kodama Y
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1747-1756. PubMed ID: 33222015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known.
    Zheng C; Huang S; Lin M; Hong B; Ni R; Dai H; Lin X; Yang J
    Hepatol Commun; 2023 Mar; 7(3):e0063. PubMed ID: 36802366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation.
    Peeraphatdit TB; Wang J; Odenwald MA; Hu S; Hart J; Charlton MR
    Hepatology; 2020 Jul; 72(1):315-329. PubMed ID: 32167613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System.
    Wang H; Yang H; Zhou X; Zhang X
    Clin Ther; 2023 Feb; 45(2):151-159. PubMed ID: 36682994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies.
    Jennings JJ; Mandaliya R; Nakshabandi A; Lewis JH
    Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):231-244. PubMed ID: 30677306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
    Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents.
    Suzman DL; Pelosof L; Rosenberg A; Avigan MI
    Liver Int; 2018 Jun; 38(6):976-987. PubMed ID: 29603856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials.
    Fujiwara Y; Horita N; Harrington M; Namkoong H; Miyashita H; Galsky MD
    Cancer Immunol Immunother; 2022 Dec; 71(12):2837-2848. PubMed ID: 35471602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis.
    Guo X; Li W; Hu J; Zhu EC; Su Q
    Eur J Clin Pharmacol; 2020 Oct; 76(10):1345-1354. PubMed ID: 32507925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of immune checkpoint inhibitors related to pulmonary adverse events: a retrospective analysis of clinical studies and network meta-analysis.
    Hong B; Du B; Chen R; Zheng C; Ni R; Liu M; Yang J
    BMC Med; 2024 Feb; 22(1):75. PubMed ID: 38373990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
    Rizzo A; Mollica V; Massari F
    Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitor-associated acute kidney injury in patients with cancer: a systematic review and meta-analysis of risk factors.
    Yan H; Tang M; Zhu W; Yang Y
    Clin Exp Nephrol; 2023 Jul; 27(7):603-612. PubMed ID: 37014535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil.
    Sato K; Inoue J; Ninomiya M; Iwata T; Sano A; Tsuruoka M; Onuki M; Sawahashi S; Ouchi K; Masamune A
    Clin J Gastroenterol; 2023 Oct; 16(5):720-725. PubMed ID: 37480423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials.
    Fujiwara Y; Horita N; Namkoong H; Galsky MD
    Eur J Cancer; 2021 Jun; 150():168-178. PubMed ID: 33906099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological response and immune-related adverse events following COVID-19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Wang Y; Chen D; Pan Y; Li H; Zhao W; Lu T; Kong W; Ding M; Wang X; Zhang G
    Rev Med Virol; 2024 Jan; 34(1):e2495. PubMed ID: 38017632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies.
    Mizuno K; Ito T; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Kawashima H; Inukai Y; Toyoda H; Yokota K; Hase T; Maeda O; Kiyoi H; Nagino M; Hibi H; Kodera Y; Fujimoto Y; Sone M; Gotoh M; Ando Y; Akiyama M; Hasegawa Y; Fujishiro M
    J Gastroenterol; 2020 Jun; 55(6):653-661. PubMed ID: 32124082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review.
    Miao K; Zhang L
    Cancer Pathog Ther; 2023 Jan; 1(1):46-55. PubMed ID: 38328612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis.
    Liu M; Cheng X; Ni R; Zheng B; Huang S; Yang J
    Front Immunol; 2022; 13():1006860. PubMed ID: 36189211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
    Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
    Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.